Liraglutide clinical study aims to improve **cardiac function** in **ischemic cardiomyopathy** patients

Ischemic cardiomyopathy (ICM) is a severe consequence of coronary artery disease, leading to heart failure and high mortality. Current treatments often fall short in fully restoring cardiac function or preventing disease progression. Liraglutide, a GLP-1 receptor agonist, has demonstrated cardioprotective effects in acute myocardial infarction, including reducing infarct size and improving left ventricular function. However, its specific benefits for patients with established ICM, a chronic condition, remain unclear, representing a significant clinical gap this study aims to address.

This clinical study, with an estimated enrollment of 90 patients, is designed to evaluate the effect of liraglutide on improving cardiac function in individuals diagnosed with ischemic cardiomyopathy. The study's start date was October 2015, with an estimated completion in October 2016. Specific details regarding the liraglutide dose, administration route, frequency, duration of treatment, and the primary endpoint measures (e.g., ejection fraction, NYHA class, 6-minute walk test) were not provided in the abstract. The study aims to determine if liraglutide can extend its previously observed benefits in acute settings to chronic ICM.